Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

BET bromodomain inhibitor… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanoma.

Artikel i vetenskaplig tidskrift
Författare Somsundar Veppil Muralidharan
Berglind Osk Einarsdottir
Joydeep Bhadury
Mattias F Lindberg
Jin Wu
Eric Campeau
Roger Olofsson Bagge
Ulrika Stierner
Lars Ny
Lisa M Nilsson
Jonas A Nilsson
Publicerad i Cell Death & Disease
Volym 8
Nummer/häfte 8
Sidor 1-7
ISSN 2041-4889
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för onkologi
Sidor 1-7
Språk en
Länkar dx.doi.org/10.1038/cddis.2017.383
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämneskategorier Cancer och onkologi

Sammanfattning

Metastatic malignant melanoma continues to be a challenging disease despite clinical translation of the comprehensive understanding of driver mutations and how melanoma cells evade immune attack. In Myc-driven lymphoma, efficacy of epigenetic inhibitors of the bromodomain and extra-terminal domain (BET) family of bromodomain proteins can be enhanced by combination therapy with inhibitors of the DNA damage response kinase ATR. Whether this combination is active in solid malignancies like melanoma, and how it relates to immune therapy, has not previously investigated. To test efficacy and molecular consequences of combination therapies cultured melanoma cells were used. To assess tumor responses to therapies in vivo we use patient-derived xenografts and B6 mice transplanted with B16F10 melanoma cells. Concomitant inhibition of BET proteins and ATR of cultured melanoma cells resulted in similar effects as recently shown in lymphoma, such as induction of apoptosis and p62, implicated in autophagy, senescence-associated secretory pathway and ER stress. In vivo, apoptosis and suppression of subcutaneous growth of patient-derived melanoma and B16F10 cells were observed. Our data suggest that ATRI/BETI combination therapies are effective in melanoma.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?